Kemp EC, Ebner MK, Ramanan S, et al. - Researchers examined how statin use influences cognition and diagnostic conversion, in individuals with cognitively normal (CN) status, mild cognitive impairment (MCI), and dementia due to Alzheimer's disease (AD-dementia). They conducted a multi-center cohort study including 1,629 adults 48 to 91 years-old with CN status, early MCI (EMCI), late MCI (LMCI), or AD-dementia at baseline; participants were followed prospectively for 24 months. The analysis revealed no correlation of statin use with longitudinal cognitive change in asymptomatic (CN) or symptomatic (LMCI or AD-dementia) participants. However, statin use seemed correlated to a slower decline in a composite memory score in prodromal (EMCI) participants. They identified no correlation of statin use with time to conversion to a more impaired diagnostic category for any diagnostic group (ie, conversion to EMCI, LMCI, or AD-dementia). These results did not support statin use as a risk factor for cognitive worsening (as indicated by the FDA black box warning).